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Abstract
Background: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur
in the treatment of hymenoptera sting allergy. The objective of the present study was to examine
the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards
hymenoptera venom in the mediterranean population of Albania.
Methods: A retrospective study was performed using the clinical reports of 37 patients with
venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily
polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy
diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT.
The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 µg/ml to 100 µg/ml.
Anaphylactic reactions were classified according to the Mueller-classification.
Results: The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom
was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-
SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT
patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an
end dose of 100 µg.
Conclusions: Rush-SIT is a reliable method for the treatment of anaphylactic reactions to
hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause
higher numbers allergic reactions than wasp or paperwasp Rush-SIT.
Background
Anaphylactic reactions caused by hymenoptera stings –
predominantly bee, wasp or paperwasp – stings are a com-
mon medical problem and account for approximately 40
deaths per year in the United Sates [1,2]. They belong to
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the most dramatic allergic diseases and may present with
an acute onset of combined local and systemic symptoms.
The prevalence of insect-sting allergies varies between 0.4
to 4% and more [3–6], and the rate of mortality has been
reported to be between 0.09 to 0.45/1000000 people/year
[4,5,7].
It is generally accepted that these systemic reactions to in-
sect stings, even if non-fatal, represent extremely unpleas-
ant and dangerous situations. Therefore, many patients
would benefit physically and psychologically from a pre-
ventive treatment. In general, the patients would prefer a
long-term treatment rather than experiencing emergency
medication and an everlasting fear about upcoming
events. However, in consideration of the relatively low
mortality rate reported, many physicians do not refer the
patients to further detailed investigations. The presently
available preventive treatment in form of specific immu-
notherapy is therefore often neglected. Also, a lack of
knowledge of immunotherapy or limited access may be
additional factors.
Apart from fire ants and mosquitoes in America, the sub-
order of hymenoptera aculeatae accounts for most allergic
reactions in Europe [8,9]. A large number of studies on the
prevalence and mortality of anaphylactic sting reactions,
the differentiation between venoms and the impact of
specific immunotherapy have been performed for indus-
trialized western countries so far. However, hymenoptera
allergies have been recognized as a worldwide health haz-
ard, reaching also the developing countries but detailed
studies for these regions have not been reported so far. In
this respect, the present study was conducted to investi-
gate the impact of Rush-SIT in a population of Albanian
hymenoptera allergy patients which were treated with
Rush-SIT.
Methods
Subjects
The present cohort consists of files collected from 37 pa-
tients who were treated with Rush-SIT for hymenoptera
sting allergy at the university hospital of Tirana between
the period of 1987 to 1996. All study subjects were native
Albanians. Before 1987, all patients were treated with
whole body extracts and therefore excluded from the
study.
Evaluation of subjects
For the assessment of the patients' history, general data
(sex, age), the age when the sting reactions happened,
time of stinging (date or month), place of stings, number
of sting-episodes, identity of insect (if possible), and
symptoms after sting episode were evaluated.
Tests
The tests consisted of intracutaneous tests in concentra-
tions of 0.001, 0.01, 0.1 and 1 µg/ml venom from bees
(apinae), wasps (vespidae, subfamily vespinae) or paper-
wasps (vespidae, subfamily polistinae). Positive test re-
sults were accepted from induration diameters of at least
5 mm.
Specific rush immunotherapy (Rush-SIT)
The Rush-SIT treatment was performed during a 4-day
hospital stay, in which a standardized scheme of escalat-
ing doses of venom was administered subcutaneoulsy:
The doses were increased from 10 -2 to 100 µg/ml of ven-
om (Table 1). The patients in the present study only re-
ceived a single venom type, and subcutaneous
maintenance injections of 100 µg venom were performed
after 7 d, 14 d and monthly for a period of 3 years.
In case of subjective or objective adverse reactions, the fur-
ther treatment was dependent on the type of reaction as
previously described [10]: Mild subjective reactions were
followed by the application of the same dose before an in-
crease. Objective reactions were followed by treatment of
the symptoms and a period of one day without further
venom application before starting with a reduced dose.
Anaphylactic reactions
Anaphylactic reactions during Rush-SIT were classified ac-
cording to the criteria of Mueller into 4 degrees [11]:
Statistics
Data correlations were analyzed using the statistical meth-
od of Spearman. For direct data comparison the χ 2-test
was used.
Results
In total, 37 patients (23 male, 14 female) with an average
age of 28 years were treated with Rush-SIT against bee ven-
om (59.5%), paperwasp venom (5.4%) and wasp venom
(35.1%). According to their history, 91.9% of patients
were admitted to the unit after experiencing an anaphylac-
tic reaction (35.1% Mueller type II and 56.8% Mueller
type III–IV) and 8.1% was treated after a mild skin reac-
tion (Mueller type I) (Table 2). The skin tests defined the
diagnosis through intracutaneous test at concentrations of
0.01  µg/ml (32.4%), 0.1 µg/ml (64.9%) or 1 µg/ml
(2.7%) (Table 2).
During Rush-SIT,16 patients (43.2%) experienced minor
reactions. These reactions were present once in 25%, twice
in 18.75%, three times in 18.75% and more than three
times in 37.5%. The reactions were found in 54.5% of pa-
tients treated with bee venom and in 30.8% in patients
treated with wasp venom (no significance, n. s.) (Table 3).
The mean frequency of reactions/injections was 3.4% (33BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/11
Page 3 of 6
(page number not for citation purposes)
reactions per 962 injections). The same index for the bee
venom was 4.7% and the one for wasp venom was 1.5%
(p < 0.01). The mean absolute frequency of first degree re-
actions for bee venom treated patients was 0.50 and the
one for patients treated with wasp venom was 0.31 (n. s.).
The same index for the second degree was 0.73 for bee
venom treated patients and 0.15 for wasp venom treated
patients with a significant difference of p < 0.01. Paper-
wasp treated patients experienced no anaphylactic reac-
tions in the present study. Also, no Mueller type III or IV
anaphylactic reaction was experienced. (Table 3).
The lowest dose causing a minor reaction was 5 µg (type
I), the lowest dose for anaphylactic reactions (type II) was
20 µg with a peak at 60 µg and no raise in frequency in
higher concentrations (Figure 1).
These reactions were treated efficiently with adrenaline in
45.4%, antihistamines in 21.2%, with both in 15.2% and
with costicosteroides (prednisolone) in combination with
adrenaline and antihistamines in 3.0% of all cases. In
15.2% a treatment was not necessary. The use of epine-
phrine in type II reactions was more frequent than in type
I reactions (20% of treated type I in contrast to 100% of
type II (p < 0.002)). 94.6% of the patients supported the
end dose 100 µg venom.
Discussion
The first documented anaphylactic reaction towards hy-
menoptera venom was the death of the Egyptian pharaoh
Menes, who died according to an Egyptian hieroglyph in
the year 2640 BC due to a wasp sting reaction [12], Since
then, many treatment options were developed and tested.
However, a specific preventive treatment has only been
available since the pioneer works of Hunt et al. 1978.
These studies demonstrated an almost complete protec-
tion by treatment with specific insect venom in contrast to
earlier studies using whole body extracts which turned out
to be equivalent to placebo [13].
The global extend of allergic diseases is still increasing
with allergic diseases being a future threat even in devel-
oping countries,. However, only little is known on specific
and preventive treatment in these countries due to eco-
Table 1: Scheme of venom rush immunotherapy. The Rush-SIT treatment was according to a 4-day scheme with increasing doses of 10 
-2 to 100 µg/ml of venom.
Day I Day II
Time Conc. [µg/ml] Volume [ml] Quantity [µg] Time Conc. [µg/ml] Volume [ml] Quantity [µg]
08.30 0.01 0.05 0.0005 08.30 1.0 0.05 0.05
09.00 0.01 0.10 0.001 09.00 1.0 0.10 0.1
09.30 0.01 0.20 0.002 09.30 1.0 0.20 0.2
10.00 0.01 0.40 0.004 10.00 1.0 0.40 0.4
10.30 0.10 0.05 0.005 10.30 10.0 0.05 0.5
11.00 0.10 0.10 0.01 11.00 10.0 0.10 1.0
11.30 0.10 0.20 0.02 11.30 10.0 0.20 2.0
12.00 0.10 0.40 0.04 12.00 10.0 0.40 4.0
12.30 1.00 0.05 0.05 12.30 100.0 0.05 5.0
Day III Day IV
Time Conc. [µg/ml] Volume [ml] Quantity [µg] Time Conc. [µg/ml] Volume [ml] Quantity [µg]
08.30 100.0 0.05 5.0 08.30 100.0 1.00 100.0
09.00 100.0 0.10 10.0
09.30 100.0 0.20 20.0
10.00 100.0 0.40 40.0
10.30 100.0 0.60 60.0
11.00 100.0 0.80 80.0
11.30 100.0 1.00 100.0BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/11
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nomical reasons. Here we studied the possibility and ad-
verse reactions of specific immunotherapy in Europe's
least developed country Albania, using hymenoptera
Rush-SIT.
The efficacy of Rush-SIT is well documented [5,14,15], but
adverse reactions including anaphylactic reactions have
been reported in up to 64% of all cases investigated [16–
20].
Here we explored the occurrence of allergic reactions dur-
ing Rush-SIT in a cohort of Albanian patients.
As immunotherapeutic scheme Rush-SIT was used, as this
treatment form enables a hospital controlled administra-
tion of venom with a success of more than 95% [21].
Even if 43.2% of the patients experienced reactions during
Rush-SIT, which is in accordance to previous reports
[15,22], the percentage related to the number of injections
is only 3.4%.
Furthermore we found that during Rush-SIT, there was no
significant difference of reactions/patient between bee ven-
om and wasp venom treated patients in Mueller grade I. In
contrast, in Mueller grade II there was a significant differ-
ence between bee venom and wasp venom treated pa-
tients. In this respect, the bee venom was found to be
more aggressive than the wasp venoms, as indicated earli-
er [15,21].
Minor anaphylactic reactions (Mueller grade I – II) were
present more frequent at the doses of 50 to 60 µg and pa-
tients who did not experience reactions up to this dose,
did not respond to higher doses later. This may be ex-
plained from the fact that the quantity of venom in a sting
is about 50 µg venom and an increased quantity such as
the Rush-SIT end dose does not lead to an increased im-
mune answer [23,24].
For the therapy of allergic reactions during Rush-SIT, dif-
ferent drugs such as adrenaline, antihistamines or corti-
costeroides may be used. A possibility to prevent allergic
reactions during Rush-SIT can be the preventive applica-
tion of these drugs. Whereas adrenaline is suitable only
for acute emergency medication in case of severe anaphy-
laxis, antihistamine medication only reduces cutaneous
symptoms such urticaria effectively [25], but no anaphy-
lactic situations. Therefore, the only efficient drugs for
prevention anaphylaxis are corticosteroids which may be
combined to antihistamines.
A recent retrospective study to determine the incidence
and nature of adverse events associated with the induction
of rush Hymenoptera venom immunotherapy in Austral-
ian patients demonstrated a high incidence of adverse sys-
temic events during the induction phase [26]. Their
conclusion, that immunotherapy should only be given by
Table 2: Clinical data of patients who received stings I.
Number of patients 37
Sex
Males 23 (62.2%)
Females 14 (37.8%)
Middle age (years) 28
Range (years) 8 – 52
Grade of sting*
I3  ( 8 . 1 % )
II 13 (35.1%)
III–IV 21 (56.8%)
Intra-cutaneous tests
Lowest concentration eliciting the diagnosis
0.01 ìg/ml 12 (32.4%)
0.1 µg/ml 24 (64.9%)
1 µg/ml 1 (2.7%)
Medication required
Adrenaline 15 (45.4%)
Antihistamines 7 (21.2%)
Adr. + Antihist 5 (15.2%)
Both + Glucocorticoides 1 (3.0%)
No medication required 5 (15.2%)
* Classified according to Mueller [11]: Grade I – urticaria, pruritus, 
malaise; Grade II – angioedema, chest tightness, nausea, vomiting, 
abdominal pain, dizziness; Grade III – dispnoea, wheeze, stridor, dys-
phagia, hoarseness; Grade IV – hypotension, collapse, loss of con-
sciousness, incontinence, cyanosis.
Figure 1
Dose-dependency of reactions. The reactions were
classiefied according to Mueller 10 with grade I – urticaria,
pruritus, malaise; grade II – angioedema, chest tightness, nau-
sea, vomiting, abdominal pain, dizziness; grade III – dispnoea,
wheeze, stridor, dysphagia, hoarseness, and grade IV – hypo-
tension, collapse, loss of consciousness, incontinence, cyano-
sis. Black: Mueller I, grey: Mueller II.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/11
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experienced staff in centres where there are facilities for re-
suscitation can be underlined by the present study. The
therapy regimen should always be updated towards the
standards published by internationally leading allergy
centers.
Conclusions
In summary, the present study describes the first investi-
gation on the use of specific immunotherapy in a develop-
ing country such as Albania and proves that this treatment
option may also be used in non-industrialized countries
with an adverse reaction profile similar to western coun-
tries.
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